1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hospital Infection Therapeutics Market

4. Market Overview
     4.1. Introduction
            4.1.1. Therapeutics Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)
            4.4.2. Market Volume/Unit Shipments Projections
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1.Regulatory Scenario by Region/globally
     5.2.Pipeline Analysis
     5.3.Reimbursement Scenario by Region/globally
     5.4.Disease Prevalence & Incidence Rate globally with key countries
     5.5.Healthcare Industry Overview
     5.6.Value Chain Analysis

6. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Forecast, by Therapeutics, 2016–2026
            6.3.1. Antibacterial Drugs
                     6.3.1.1. Cell Wall Synthesis Inhibitors
                     6.3.1.2. Protein Synthesis Inhibitors
                     6.3.1.3. Others
            6.3.2. Antifungal Drugs
                     6.3.2.1. Caspofungin
                     6.3.2.2. Amphotericin B
                     6.3.2.3. Others
            6.3.3. Antiviral Drugs
            6.3.4. Others
     6.4. Market Attractiveness, by Therapeutics

7. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Infection
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Forecast, by Infection, 2016–2026
            7.3.1. Hospital Acquired Pneumonia
            7.3.2. Urinary Tract Infections
            7.3.3. Gastrointestinal Disorders
            7.3.4. Bloodstream Infections
            7.3.5. Surgical Site Infections
            7.3.6. Other Hospital Infections
     7.4. Market Attractiveness, by Infection

8. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Region
     8.1. Key Findings
     8.2. Market Forecast, by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
     8.3. Market Attractiveness, by Country/Region

9. North America Hospital Infection Therapeutics Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. Market Forecast, by Therapeutics, 2016–2026
            9.2.1. Antibacterial Drugs
                     9.2.1.1. Cell Wall Synthesis Inhibitors
                     9.2.1.2. Protein Synthesis Inhibitors
                     9.2.1.3. Others
            9.2.2. Antifungal Drugs
                     9.2.2.1. Caspofungin
                     9.2.2.2. Amphotericin B
                     9.2.2.3. Others
            9.2.3. Antiviral Drugs
            9.2.4. Others
     9.3. Market Forecast, by Infection, 2016–2026
            9.3.1. Hospital Acquired Pneumonia
            9.3.2. Urinary Tract Infections
            9.3.3. Gastrointestinal Disorders
            9.3.4. Bloodstream Infections
            9.3.5. Surgical Site Infections
            9.3.6. Other Hospital Infections
     9.4. Market Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada
     9.5. Market Attractiveness Analysis
            9.5.1. By Therapeutics
            9.5.2. By Infection
            9.5.3. By Country

10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Market Forecast, by Therapeutics, 2016–2026
            10.2.1. Antibacterial Drugs
                     10.2.1.1. Cell Wall Synthesis Inhibitors
                     10.2.1.2. Protein Synthesis Inhibitors
                     10.2.1.3. Others
            10.2.2. Antifungal Drugs
                     10.2.2.1. Caspofungin
                     10.2.2.2. Amphotericin B
                     10.2.2.3. Others
            10.2.3. Antiviral Drugs
            10.2.4. Others
     10.3. Market Forecast, by Infection, 2016–2026
            10.3.1. Hospital Acquired Pneumonia
            10.3.2. Urinary Tract Infections
            10.3.3. Gastrointestinal Disorders
            10.3.4. Bloodstream Infections
            10.3.5. Surgical Site Infections
            10.3.6. Other Hospital Infections
     10.4. Market Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. France
            10.4.4. Spain
            10.4.5. Italy
            10.4.6. Russia
            10.4.7. Rest of Europe
     10.5. Market Attractiveness Analysis
            10.5.1. By Therapeutics
            10.5.2. By Infection
            10.5.3. By Country/Sub-region

11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2.Market Forecast, by Therapeutics, 2016–2026
            11.2.1. Antibacterial Drugs
                     11.2.1.1. Cell Wall Synthesis Inhibitors
                     11.2.1.2. Protein Synthesis Inhibitors
                     11.2.1.3. Others
            11.2.2. Antifungal Drugs
                     11.2.2.1. Caspofungin
                     11.2.2.2. Amphotericin B
                     11.2.2.3. Others
            11.2.3. Antiviral Drugs
            11.2.4. Others
     11.3.Market Forecast, by Infection, 2016–2026
            11.3.1. Hospital Acquired Pneumonia
            11.3.2. Urinary Tract Infections
            11.3.3. Gastrointestinal Disorders
            11.3.4. Bloodstream Infections
            11.3.5. Surgical Site Infections
            11.3.6. Other Hospital Infections
     11.4.Market Forecast, by Country/Sub-region, 2016–2026
            11.4.1. China
            11.4.2. Japan
            11.4.3. India
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific
     11.5.Market Attractiveness Analysis
            11.5.1. By Therapeutics
            11.5.2. By Infection
            11.5.3. By Country/Sub-region

12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2.Market Forecast, by Therapeutics, 2016–2026
            12.2.1. Antibacterial Drugs
                     12.2.1.1. Cell Wall Synthesis Inhibitors
                     12.2.1.2. Protein Synthesis Inhibitors
                     12.2.1.3. Others
            12.2.2. Antifungal Drugs
                     12.2.2.1. Caspofungin
                     12.2.2.2. Amphotericin B
                     12.2.2.3. Others
            12.2.3. Antiviral Drugs
            12.2.4. Others
     12.3.Market Forecast, by Infection, 2016–2026
            12.3.1. Hospital Acquired Pneumonia
            12.3.2. Urinary Tract Infections
            12.3.3. Gastrointestinal Disorders
            12.3.4. Bloodstream Infections
            12.3.5. Surgical Site Infections
            12.3.6. Other Hospital Infections
     12.4.Market Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America
     12.5.Market Attractiveness Analysis
            12.5.1. By Therapeutics
            12.5.2. By Infection
            12.5.3. By Country/Sub-region

13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2.Market Forecast, by Therapeutics, 2016–2026
            13.2.1. Antibacterial Drugs
                     13.2.1.1. Cell Wall Synthesis Inhibitors
                     13.2.1.2. Protein Synthesis Inhibitors
                     13.2.1.3. Others
            13.2.2. Antifungal Drugs
                     13.2.2.1. Caspofungin
                     13.2.2.2. Amphotericin B
                     13.2.2.3. Others
            13.2.3. Antiviral Drugs
            13.2.4. Others
     13.3.Market Forecast, by Infection, 2016–2026
            13.3.1. Hospital Acquired Pneumonia
            13.3.2. Urinary Tract Infections
            13.3.3. Gastrointestinal Disorders
            13.3.4. Bloodstream Infections
            13.3.5. Surgical Site Infections
            13.3.6. Other Hospital Infections
     13.4.Market Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. South Africa
            13.4.3. Israel
            13.4.4. Rest of Middle East & Africa
     13.5.Market Attractiveness Analysis
            13.5.1. By Therapeutics
            13.5.2. By Infection
            13.5.3. By Country/Sub-region

14. Competition Landscape
     14.1.Market Player – Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2017)
     14.3.Market Footprint Analysis
     14.4. Competitive Business Strategies
     14.5. Company Profiles
            14.5.1. Allergan
                     14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.1.2. Product Portfolio
                     14.5.1.3. SWOT Analysis
                     14.5.1.4. Strategic Overview
                     14.5.1.5. Financial Overview
            14.5.2. AstraZeneca
                     14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.2.2. Product Portfolio
                     14.5.2.3. SWOT Analysis
                     14.5.2.4. Strategic Overview
                     14.5.2.5. Financial Overview
            14.5.3. Basilea Pharmaceutica Ltd.
                     14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.3.2. Product Portfolio
                     14.5.3.3. SWOT Analysis
                     14.5.3.4. Strategic Overview
                     14.5.3.5. Financial Overview
            14.5.4. Bayer AG
                     14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.4.2. Product Portfolio
                     14.5.4.3. SWOT Analysis
                     14.5.4.4. Strategic Overview
                     14.5.4.5. Financial Overview
            14.5.5. Bristol-Myers Squibb Company
                     14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.5.2. Product Portfolio
                     14.5.5.3. SWOT Analysis
                     14.5.5.4. Strategic Overview
                     14.5.5.5. Financial Overview
            14.5.6. F. Hoffman-La Roche Ltd.
                     14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.6.2. Product Portfolio
                     14.5.6.3. SWOT Analysis
                     14.5.6.4. Strategic Overview
                     14.5.6.5. Financial Overview
            14.5.7. GlaxoSmithKline plc.
                     14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.7.2. Product Portfolio
                     14.5.7.3. SWOT Analysis
                     14.5.7.4. Strategic Overview
                     14.5.7.5. Financial Overview
            14.5.8. Johnson & Johnson Services, Inc.
                     14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.8.2. Product Portfolio
                     14.5.8.3. SWOT Analysis
                     14.5.8.4. Strategic Overview
                     14.5.8.5. Financial Overview
            14.5.9. Merck & Co., Inc.
                     14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.9.2. Product Portfolio
                     14.5.9.3. SWOT Analysis
                     14.5.9.4. Strategic Overview
                     14.5.9.5. Financial Overview
            14.5.10. Pfizer Inc.
                     14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.10.2. Product Portfolio
                     14.5.10.3. SWOT Analysis
                     14.5.10.4. Strategic Overview
                     14.5.10.5. Financial Overview
            14.5.11. Sanofi
                     14.5.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.11.2. Product Portfolio
                     14.5.11.3. SWOT Analysis
                     14.5.11.4. Strategic Overview
                     14.5.11.5. Financial Overview

List of Tables

Table 01 WHO priority list and drug candidates in pre-clinical and clinical development
Table 02 Pipeline Analysis of Hospital Infection Therapeutics (1/5)
Table 03 Pipeline Analysis of Hospital Infection Therapeutics (2/5)
Table 04 Pipeline Analysis of Hospital Infection Therapeutics (3/5)
Table 05 Pipeline Analysis of Hospital Infection Therapeutics (4/5)
Table 06 Pipeline Analysis of Hospital Infection Therapeutics (5/5)
Table 07 Disease Prevalence & Incidence Rate Globally, by Key Countries
Table 08 Healthcare Industry Overview
Table 09 Incidence Rate (per 100,000 population) of S. aureus bacteremia, U.K., 2013 (1/2)
Table 10 Table: Incidence Rate (per 100,000 population) of S. aureus bacteremia, U.K., 2013 (2/2)
Table 11 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 12 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
Table 13 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
Table 14 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 15 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 16 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 17 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 18 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
Table 19 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
Table 20 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 21 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 23 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
Table 24 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
Table 25 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 26 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 27 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 28 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
Table 29 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
Table 30 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 31 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 32 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 33 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics: Anti-bacterial Drugs, 2016–2026
Table 34 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics: Anti-fungal Drugs, 2016–2026
Table 35 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 36 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 37 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 38 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Anti-bacterial Drugs, 2016–2026
Table 39 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Anti-fungal Drugs, 2016–2026
Table 40 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026

List of Figures
 
Figure 01 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 02 Global Hospital Infection Therapeutics Market Value Share (%), by Therapeutics (2017)
Figure 03 Global Hospital Infection Therapeutics Market Value Share (%), by Region (2017)
Figure 04 Global Hospital Infection Therapeutics Market Value Share (%), by Infection (2017)
Figure 05 Percentage Distribution of Population Aged 65 and Over, by Region: 2015
Figure 06 Percentage Distribution of Population Aged 65 and Over, by Region: 2050
Figure 07 Regulatory Approval Process - U.S.
Figure 08 Regulatory Approval Process - Europe
Figure 09 Regulatory Approval Process - Japan
Figure 10 Global Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 11 Global Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 12 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-bacterial Drugs, 2016–2026
Figure 13 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-fungal Drugs, 2016–2026
Figure 14 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-viral Drugs, 2016–2026
Figure 15 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
Figure 16 Global Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 17 Global Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 18 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Acquired Pneumonia, 2016–2026
Figure 19 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Urinary Tract Infections, 2016–2026
Figure 20 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gastrointestinal Disorders, 2016–2026
Figure 21 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bloodstream Infections, 2016–2026
Figure 22 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Site Infections, 2016–2026
Figure 23 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Other Hospital Infections, 2016–2026
Figure 24 Global Hospital Infection Therapeutics Market Value Share (%), by Region, 2017 and 2026
Figure 25 Global Hospital Infection Therapeutics Market Attractiveness, by Region, 2018–2026
Figure 26 North America Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 27 North America Hospital Infection Therapeutics Market Value Share (%), by Country, 2017 and 2026
Figure 28 North America Hospital Infection Therapeutics Market Attractiveness, by Country, 2018–2026
Figure 29 North America Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 30 North America Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 31 North America Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 32 North America Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 33 Europe Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 34 Europe Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 35 Europe Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 36 Europe Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 37 Europe Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 38 Europe Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 39 Europe Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 40 Asia Pacific Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 41 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 42 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 43 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 44 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 45 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 46 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 47 Latin America Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 48 Latin America Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region,
Figure 49 Latin America Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 50 Latin America Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 51 Latin America Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 52 Latin America Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 53 Latin America Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 54 Middle East & Africa Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 55 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 56 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 57 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 58 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 59 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 60 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 61 Global Hospital Infection Therapeutics Market Share, by Company, 2017
Figure 62 Competition Matrix (1/2)
Figure 63 Competition Matrix (2/2)

.